Question 1

I was diagnosed with a breast tumor at age 38 and my genetic panel showed a RAD51 variant of uncertain significance. How should I interpret this result for my cancer risk?

Accepted Answer

variant of uncertain significance (VUS) means current evidence does not clearly link the change to increased breast cancer risk. Management should follow standard breast‑cancer screening guidelines (annual mammogram, consider MRI) and family history assessment. If additional data emerge (e.g., functional studies or co‑segregation with disease in families), the classification may be updated. Discuss with a genetics counselor for personalized recommendations.

Question 2

Are RAD51 mutations inherited, and what is the recurrence risk for my children?

Accepted Answer

Pathogenic RAD51 mutations linked to cancer predisposition are typically inherited in an autosomal dominant manner. If a definitive pathogenic variant is confirmed, each child has a 50 % chance of inheriting it. However, many RAD51 alterations identified in cancer panels are somatic (present only in tumor tissue) and not passed to offspring. Confirm whether the variant is germline (found in blood DNA) before assessing recurrence risk.

Question 3

If a family member has a known pathogenic RAD51 deletion, should we avoid certain medical procedures that involve DNA damage?

Accepted Answer

Individuals with RAD51 haploinsufficiency may have reduced capacity to repair double‑strand DNA breaks. While routine medical care is safe, clinicians often consider minimizing exposure to high‑dose ionizing radiation (e.g., certain CT scans) and may prefer alternative imaging when feasible. Additionally, some chemotherapeutic agents that cause DNA breaks could pose higher toxicity; oncologists tailor regimens based on the patient’s genetic background.

Question 4

My son has congenital mirror movement disorder. The doctor mentioned a RAD51 mutation. What does this mean for his development and future therapies?

Accepted Answer

In congenital mirror movement disorder, certain RAD51 missense mutations disrupt the protein’s ability to form functional complexes, leading to abnormal wiring of the corticospinal tracts. This results in involuntary mirroring of voluntary movements. The condition is usually non‑progressive; therapy focuses on occupational and physical therapy to improve motor control. Research into gene‑specific therapies is ongoing, but currently management is supportive.

RAD51 gene

Normal Function

Health Conditions Related to Genetic Changes

Congenital mirror movement disorder

Breast cancer

Fanconi anemia

Other Names for This Gene

Genomic Location

Frequently Asked Questions